Literature DB >> 11533238

Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation.

A Osborne1, H Zhang, W M Yang, E Seto, G Blanck.   

Abstract

Expression of the retinoblastoma tumor suppressor protein (Rb) is required for gamma interferon (IFN-gamma)-inducible major histocompatibility complex class II gene expression and transcriptionally productive HLA-DRA promoter occupancy in several human tumor cell lines. Treatment of these Rb-defective tumor cell lines with histone deacetylase (HDAC) inhibitors rescued IFN-gamma-inducible HLA-DRA and -DRB mRNA and cell surface protein expression, demonstrating repression of these genes by endogenous cellular HDAC activity. Additionally, Rb-defective, transcriptionally incompetent tumor cells retained the HLA-DRA promoter DNase I-hypersensitive site. Thus, HDAC-mediated repression of the HLA-DRA promoter occurs following the establishment of an apparent nucleosome-free promoter region and before transcriptionally productive occupancy of the promoter by the required transactivators. Repression of HLA-DRA promoter activation by HDAC activity likely involves a YY1 binding element located in the first exon of the HLA-DRA gene. Chromatin immunoprecipitation experiments localized YY1 to the HLA-DRA gene in Rb-defective tumor cells. Additionally, mutation of the YY1 binding site prevented repression of the promoter by HDAC1 and partially prevented activation of the promoter by trichostatin A. Mutation of the octamer element also significantly reduced the ability of HDAC1 to confer repression of inducible HLA-DRA promoter activation. Treatment of Rb-defective tumor cells with HDAC inhibitors greatly reduced the DNA binding activity of Oct-1, a repressor of inducible HLA-DRA promoter activation. These findings represent the first evidence that HDAC activity can repress IFN-gamma-inducible HLA class II gene expression and also demonstrate that HDAC activity can contribute to promoter repression following the establishment of a DNase I-hypersensitive chromatin conformation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533238      PMCID: PMC99796          DOI: 10.1128/MCB.21.19.6495-6506.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  67 in total

1.  Co-stimulation of promoter for low density lipoprotein receptor gene by sterol regulatory element-binding protein and Sp1 is specifically disrupted by the yin yang 1 protein.

Authors:  M K Bennett; T T Ngo; J N Athanikar; J M Rosenfeld; T F Osborne
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

Review 2.  Tumor immunotherapy: the tumor cell as an antigen-presenting cell.

Authors:  S Ostrand-Rosenberg
Journal:  Curr Opin Immunol       Date:  1994-10       Impact factor: 7.486

3.  Transforming growth factor beta 1 repression of the HLA-DR alpha gene is mediated by conserved proximal promoter elements.

Authors:  A M Reimold; C J Kara; J W Rooney; L H Glimcher
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

4.  MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.

Authors:  S Baskar; V Azarenko; E Garcia Marshall; E Hughes; S Ostrand-Rosenberg
Journal:  Cell Immunol       Date:  1994-04-15       Impact factor: 4.868

5.  YY1 is a negative regulator of transcription of three sterol regulatory element-binding protein-responsive genes.

Authors:  J Ericsson; A Usheva; P A Edwards
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

6.  Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells.

Authors:  Y Lu; G D Ussery; M M Muncaster; B L Gallie; G Blanck
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

7.  Activation of the mouse cytokeratin A (endo A) gene in teratocarcinoma F9 cells by the histone deacetylase inhibitor Trichostatin A.

Authors:  T Miyashita; H Yamamoto; Y Nishimune; M Nozaki; T Morita; A Matsushiro
Journal:  FEBS Lett       Date:  1994-10-17       Impact factor: 4.124

8.  CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors.

Authors:  K L Wright; B J Vilen; Y Itoh-Lindstrom; T L Moore; G Li; M Criscitiello; P Cogswell; J B Clarke; J P Ting
Journal:  EMBO J       Date:  1994-09-01       Impact factor: 11.598

9.  Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.

Authors:  R F Wang; X Wang; S A Rosenberg
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

10.  Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.

Authors:  S Baskar; L Glimcher; N Nabavi; R T Jones; S Ostrand-Rosenberg
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  12 in total

1.  Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors.

Authors:  Kevin Cronin; Hernando Escobar; Karoly Szekeres; Eduardo Reyes-Vargas; Alan L Rockwood; Mark C Lloyd; Julio C Delgado; George Blanck
Journal:  Hum Vaccin Immunother       Date:  2013-01-17       Impact factor: 3.452

2.  MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development.

Authors:  John M Yavorski; George Blanck
Journal:  Mol Clin Oncol       Date:  2017-09-29

3.  An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment.

Authors:  Karoly Szekeres; Rudra Koul; James Mauro; Mark Lloyd; Joseph Johnson; George Blanck
Journal:  Exp Mol Pathol       Date:  2014-09-16       Impact factor: 3.362

4.  The POU transcription factor Oct-1 represses virus-induced interferon A gene expression.

Authors:  Thibault Mesplède; Marie-Laure Island; Nicolas Christeff; Fahrettin Petek; Janine Doly; Sébastien Navarro
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

5.  Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency.

Authors:  Felicia D Goodrum; Craig T Jordan; Kevin High; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

Review 6.  The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy.

Authors:  Jack Hutcheson; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes.

Authors:  Rajini Mudhasani; Joseph D Fontes
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

8.  Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.

Authors:  Eleni Zika; Susanna F Greer; Xin-Sheng Zhu; Jenny P-Y Ting
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

Review 9.  The Yin and Yang of YY1 in the nervous system.

Authors:  Ye He; Patrizia Casaccia-Bonnefil
Journal:  J Neurochem       Date:  2008-05-15       Impact factor: 5.372

10.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.

Authors:  A Nazmul H Khan; Christopher J Gregorie; Thomas B Tomasi
Journal:  Cancer Immunol Immunother       Date:  2007-11-28       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.